{"data":[{"accessionNo":"0001764435-26-000003","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-30","reportingPerson":"Yi Shi","reportingCik":null,"personType":"IN","sharesOwned":11858655,"percentOfClass":11.1,"filedAt":"2026-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001764435-26-000003","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-30","reportingPerson":"LAV Biosciences Fund V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":11243179,"percentOfClass":10.5,"filedAt":"2026-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001764435-26-000003","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-30","reportingPerson":"LAV Fund VI Opportunities, L.P.","reportingCik":null,"personType":"PN","sharesOwned":307738,"percentOfClass":0.3,"filedAt":"2026-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001764435-26-000003","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-30","reportingPerson":"LAV Fund VI, L.P.","reportingCik":null,"personType":"PN","sharesOwned":307738,"percentOfClass":0.3,"filedAt":"2026-10-16","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Capital Management, LLC","reportingCik":"0001853723","personType":"OO","sharesOwned":9936661,"percentOfClass":9.3,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"Simeon George","reportingCik":null,"personType":"IN","sharesOwned":9936661,"percentOfClass":9.3,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Capital Fund I Aggregator, LP","reportingCik":null,"personType":"PN","sharesOwned":5554094,"percentOfClass":5.2,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Capital Partners I, LP","reportingCik":null,"personType":"PN","sharesOwned":5554094,"percentOfClass":5.2,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Capital Opportunities Fund I, LP","reportingCik":null,"personType":"PN","sharesOwned":1953505,"percentOfClass":1.8,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Capital Opportunities Partners I, LP","reportingCik":null,"personType":"PN","sharesOwned":1953505,"percentOfClass":1.8,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Co-Invest III Manager, LLC","reportingCik":null,"personType":"OO","sharesOwned":1836469,"percentOfClass":1.7,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Co-Invest III, LLC","reportingCik":null,"personType":"OO","sharesOwned":1836469,"percentOfClass":1.7,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"SR One Capital SMA Partners, LP","reportingCik":null,"personType":"PN","sharesOwned":592593,"percentOfClass":0.6,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001072613-26-000820","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-09-28","reportingPerson":"AMZL, LP","reportingCik":null,"personType":"PN","sharesOwned":592593,"percentOfClass":0.6,"filedAt":"2026-10-05","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0000947871-26-000917","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"COMMON STOCK","eventDate":"2026-09-28","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":"0001055951","personType":"IA","sharesOwned":14913764,"percentOfClass":14,"filedAt":"2026-10-02","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0000947871-26-000917","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"COMMON STOCK","eventDate":"2026-09-28","reportingPerson":"ORBIMED CAPITAL GP VII LLC","reportingCik":"0001760648","personType":"OO","sharesOwned":14325529,"percentOfClass":13.4,"filedAt":"2026-10-02","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0000947871-26-000917","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"COMMON STOCK","eventDate":"2026-09-28","reportingPerson":"ORBIMED ADVISORS ISRAEL II LTD","reportingCik":"0001682093","personType":"CO","sharesOwned":9292025,"percentOfClass":8.7,"filedAt":"2026-10-02","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0000947871-26-000917","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"COMMON STOCK","eventDate":"2026-09-28","reportingPerson":"ORBIMED ISRAEL GP II, L.P.","reportingCik":"0001682090","personType":"PN","sharesOwned":9292025,"percentOfClass":8.7,"filedAt":"2026-10-02","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0000947871-26-000917","formType":"SCHEDULE 13D","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"COMMON STOCK","eventDate":"2026-09-28","reportingPerson":"OrbiMed Genesis GP LLC","reportingCik":"0001808744","personType":"OO","sharesOwned":588235,"percentOfClass":0.6,"filedAt":"2026-10-02","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"},{"accessionNo":"0001193125-26-410626","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001802369","issuerName":"ADARx Pharmaceuticals, Inc.","ticker":"ADRX","cusip":"00654F105","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-09-24","reportingPerson":"BCLS Fund III Investments, LP","reportingCik":null,"personType":"PN","sharesOwned":6728970,"percentOfClass":6.3,"filedAt":"2026-10-01","canonicalUrl":"https://xoomar.com/markets/stocks/adrx"}],"updatedAt":"2026-10-24T08:48:35.343Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/adrx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}